Landing - Corporate Profile Text
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
More events are coming soon.
May 31, 2023HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
May 31, 2023HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
May 11, 2023HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights